RHIZEN PHARMACEUTICALS
Rhizen is a clinical-stage biopharmaceutical company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders. Rhizen’s proprietary IP in these areas is aimed at generating first-best-early in class, compounds that are expected to offer novel therapeutic options for these significant unmet medical needs. Rhizen operates as a virtual company leveraging the best efficiencies through out sourcing to globally reputed laboratories while progressing from pre-clinical to clinical development.
RHIZEN PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Pharmaceutical
Address:
La Chaux-de-fonds, Neuchatel, Switzerland
Country:
Switzerland
Website Url:
http://www.rhizen.com
Status:
Active
Contact:
+41 32 580 0113
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Apache
Similar Organizations
Bio-Cancer Treatment
Bio-Cancer Treatment is a clinical-stage biopharmaceutical company focused on the research and development of innovative biologics.
N-Gene
N-Gene is a clinical-stage bio-pharmaceutical drugs designed to focus on the development of proprietary synthetic small molecules.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Current Employees Featured
Founder
Official Site Inspections
http://www.rhizen.com
- Host name: ec2-65-1-252-108.ap-south-1.compute.amazonaws.com
- IP address: 65.1.252.108
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Rhizen Pharmaceuticals"
Rhizen – Pharmaceuticals AG
The Rhizen Journey! Our journey to be a leading biopharmaceutical company developing differentiated products through cutting-edge science and strategic partnerships started in …See details»
About Us – Rhizen
Our Journey to be a Leading Discovery & Development Company Focusing on Differentiated Products Through Cutting-edge Science and Strategic Partnerships. Establishment of clinical …See details»
About Us2 – Rhizen
Leading the team that helps articulate the intended positioning, market potential & commercial strategy for Rhizen’s pipeline assets. 20+ yrs as a drug discovery scientist, project manager, …See details»
Rhizen Pharmaceuticals - Crunchbase Company Profile …
Rhizen is a clinical-stage biopharmaceutical company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, …See details»
Rhizen Pharmaceuticals AG - LinkedIn
Developing The Next Generation Medicines That Will Lead The Fight Against Cancer | Rhizen is Swiss HQ biotech focused on discovery and development of innovative, small molecule drugs for the...See details»
Rhizen Pharmaceuticals AG – Swiss Biotech
Rhizen is Swiss HQ biotech focused on discovery & development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. The company has demonstrated …See details»
Rhizen success story - Basel Area Business & Innovation
The biopharmaceutical company Rhizen transferred their headquarters from La Chaux-de-Fonds in the canton of Neuenburg to Basel-Stadt in December 2020. Founded in 2008 as a discovery and development company, Rhizen has …See details»
Rhizen Pharmaceuticals - Products, Competitors, Financials, …
Rhizen Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative medicines in the oncology and inflammation sectors. Use the CB …See details»
Rhizen Pharmaceuticals - Craft
Rhizen Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs that target signal transduction networks and ion …See details»
Rhizen Pharmaceuticals AG Announces First Patient …
Sep 21, 2021 · Randomized, placebo-controlled Phase 2 study is designed to evaluate the effect of RP7214 on viral load & clearance, disease biomarkers and clinical improvement in patients’ status along with the...See details»
Rhizen Pharmaceuticals AG Presents Data on Its …
Apr 9, 2022 · BASEL, Switzerland-- ( BUSINESS WIRE )--Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company,...See details»
Our Science - Rhizen
We are pursuing a highly promising pipeline of next generation oncology leads by creating discovery platforms around validated oncogenic pathways with clinical de-risking.See details»
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a …
Nov 1, 2021 · BASEL, Switzerland--(BUSINESS WIRE)--Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focused …See details»
RP 6503, Novartis to develop and commercialize Rhizen’s inhaled …
Apr 2, 2016 · Novartis to develop and commercialize Rhizen’s inhaled dual PI3K-delta gamma inhibitor and related compounds worldwide. The immune pipeline includes ‘dual PI3K inhibitors …See details»
Rhizen drug secures approval in the USA
Oct 2, 2021 · Rhizen Pharmaceuticals has discovered Umbralisib, a medication that has now been approved by the US Food and Drug Administration (FDA) for the treatment of patients …See details»
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a …
Oct 13, 2021 · BASEL, Switzerland-- ( BUSINESS WIRE )--Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed …See details»
Rhizen begins dosing in Phase I/Ib advanced solid tumours …
Nov 1, 2021 · Rhizen Pharmaceuticals has initiated dosing in the Phase I/Ib clinical trial of its new poly (ADP-ribose) polymerase (PARP) inhibitor (RP12146) in advanced solid tumour patients …See details»
News and Events / Media - Rhizen
At Rhizen we practice. Fostering a culture of cutting-edge innovation as has been evidenced by our pivotal leadership in the “Targeted Drugs for Oncology & Inflammation” space through our …See details»
Rhizen Pharmaceuticals Begins Phase II Trial of PI3K Inhibitor in ...
Oct 14, 2021 · NEW YORK – Rhizen Pharmaceuticals on Wednesday dosed the first patient in a Phase II trial of tenalisib, an isoform selective dual PI3K inhibitor with additional SIK3 activity, …See details»
Rhizin: Uses, Dosage, Side Effects, FAQ - MedicinesFAQ
Sep 19, 2023 · Rhizin is used for the treatment of seasonal allergic rhinitis and conjunctivitis, perennial allergic rhinitis, pruritus and urticaria. It is also used in allergen induced asthma.See details»